Natera (NASDAQ:NTRA) Insider Sells 15,160 Shares of Stock

Key Points

• Natera insider Solomon Moshkevich sold 15,160 shares at an average price of $326.89, generating approximately $4.96 million. The sale, conducted under a Rule 10b5-1 plan, covered tax obligations tied to vested equity awards and reduced his holdings by 12.03%.
• Natera shares rose 0.8% to $327.67, near the company’s 52-week high of $343.18. The stock has a market capitalization of approximately $47.23 billion and is up significantly from its one-year low of $157.43.
• The company reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its adjusted loss of $0.47 per share beat estimates. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $319.38.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 15,160 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares of the company's stock, valued at $36,238,698.51. The trade was a 12.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.

Natera Stock Up 0.8%

NTRA traded up $2.50 during trading on Thursday, reaching $327.67. The stock had a trading volume of 708,176 shares, compared to its average volume of 1,439,570. The stock has a 50 day moving average of $291.29 and a two-hundred day moving average of $237.00. The firm has a market capitalization of $47.23 billion, a price-to-earnings ratio of -240.93 and a beta of 1.54. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same period last year, the firm earned ($0.74) EPS. On average, research analysts forecast that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its holdings in shares of Natera by 28,373.5% during the second quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company's stock worth $15,289,364,000 after acquiring an additional 56,126,974 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. BlackRock Inc. acquired a new position in Natera in the 2nd quarter worth about $2,962,770,000. Wellington Management Group LLP increased its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after purchasing an additional 72,087 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NTRA. Leerink Partners set a $330.00 target price on shares of Natera in a research note on Friday, August 7th. The Goldman Sachs Group started coverage on shares of Natera in a research report on Friday, June 5th. They issued a "neutral" rating and a $245.00 price target on the stock. Morgan Stanley reiterated an "overweight" rating and set a $355.00 price objective on shares of Natera in a research report on Monday, August 10th. TD Cowen upped their price objective on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Finally, Wells Fargo & Company raised their target price on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source